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Background

• Antimicrobial regimen for methicillin- resistant Staphylococcus
•
•
•

aureus (MRSA) coverage with antibiotics such as vancomycin are
recommended for empiric use in the treatment of suspected MRSA (1-2)
Nasal MRSA Polymerase Chain Reaction (PCR) assay has shown high
negative predictive value for MRSA pneumonia
Previous retrospective studies in the inpatient setting have demonstrated
no difference in hospital mortality or decreased exposure to broadspectrum antimicrobials (vancomycin) with MRSA PCR utilization for deescalation of therapy(3-5)
Early utilization of MRSA PCR by pharmacists in the ED will lead to early
de-escalation or avoidance of vancomycin in patients with suspected
pneumonia and MRSA risk factors

Objectives

Utilize MRSA PCR assay by pharmacist in the ED for early de-escalation or
avoidance of vancomycin in patients with suspected pneumonia and MRSA
risk factors

Methods

Design:
Single center, retrospective cohort study
Groups:
Control Group: Historical cohort, no pharmacist MRSA
PCR intervention and received IV vancomycin
Intervention Group: Pharmacist initiated MRSA PCR assay
Inclusion Criteria:

•Patients presenting the Emergency Department
between 8-1-2019 and 9-30-2020
•≥ 18 years
•Radiographic diagnosis of pneumonia
•Patients with empiric vancomycin ordered
Exclusion Criteria:

•Currently on chemotherapy for malignancy or with
neutropenic fever
•Patients with lung transplant or cystic fibrosis
•Prior positive MRSA in a blood, sputum culture, or
suspected MRSA infection elsewhere
•Patients with concomitant empiric agents with MRSA
activity (e.g., linezolid, ceftaroline)

Methods
Sample Size:

38 patients (patient enrollment ongoing)

Primary Endpoints:

Results Continued
Number of patients who received one dose
of Vancomycin prior to MRSA PCR Result

•Number of patients who received only one dose of vancomycin
prior to MRSA PCR result

Secondary Endpoints:

•Number of patients in whom empiric vancomycin was avoided in
the Emergency Department
•Number of patients who had positive MRSA sputum or blood
culture despite negative MRSA PCR results
•Hospital length of stay and hospital mortality
• Need for vancomycin level monitoring

Results
Conclusion
• More patients in intervention group had empiric dose of
vancomycin held prior to MRSA PCR result
• More patients in the control group had vancomycin levels
drawn
• Data collection is currently ongoing, and results presented
are preliminary data
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